Biological Response of Nasopharyngeal Carcinoma to Radiation Therapy: A Pilot Study Using Serial ¹⁸F-FDG PET/CT Scans

REFERENCES

• Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009;27: 3684–3690.
   PubMed Web of Science ®Google Scholar
• Yu KH, Leung SF, Tung SY, Zee B, Chua DT, Sze WM, Law SC, Kam MK, Leung TW, Sham JS, Lee AW, Au JS, Hui EP, Sze WK, Cheng AC, Yau TK, Ngan RK, Wong FC, Au GK, Chan AT. Hong Kong Nasopharyngeal Carcinoma Study Group. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005;27:397–405.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Shakespeare TP, Tan LK, Goh BC, Cooper JS. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma. Head Neck 2004;26:389–395.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Kong L, Shakespeare TP, Loh KS, Zhang Q, Tan KS, Lee KM. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma. Oral Oncol 2008;44: 703–709.
   PubMed Web of Science ®Google Scholar
• Qiu S, Lin S, Tham IW, Pan J, Lu J, Lu JJ. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;83:676–683.
   PubMed Web of Science ®Google Scholar
• Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 2011;80:661–668.
   PubMed Web of Science ®Google Scholar
• Kong L, Lu JJ, Liss AL, Hu C, Guo X, Wu Y, Zhang Y. Radiation-induced cranial nerve palsy: a cross-sectional study of nasopharyngeal cancer patients after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:1421–1427.
   PubMed Web of Science ®Google Scholar
• Kwong DL, Nicholls J, Wei WI, Chua DT, Sham JS, Yuen PW, Cheng AC, Wan KY, Kwong PW, Choy DT. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer 1999;85:1446–1453.
   PubMed Web of Science ®Google Scholar
• Ma X, Lu JJ, Loh KS, Shakespeare TP, Thiagarajan A, Goh BC, Tan KS. Role of computed tomography imaging in predicting response of nasopharyngeal carcinoma to definitive radiation therapy. Laryngoscope 2006;116:2162–2165.
   PubMed Web of Science ®Google Scholar
• Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50:74S–88S.
   PubMed Web of Science ®Google Scholar
• Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998;16:3550–3555.
   PubMed Web of Science ®Google Scholar
• Tsai MH, Shiau YC, Kao CH, Shen YY, Lin CC, Lee CC. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 2002;128:279–282.
   PubMed Web of Science ®Google Scholar
• Yen RF, Hung RL, Pan MH, Wang YH, Huang KM, Lui LT, Kao CH. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003;98:283–287.
   PubMed Web of Science ®Google Scholar
• Ng SH, Joseph CT, Chan SC, Ko SF, Wang HM, Liao CT, Chang YC, Lin WJ, Fu YK, Yen TC. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 2004;45:1669–1676.
   PubMed Web of Science ®Google Scholar
• Liu T, Xu W, Yan WL, Ye M, Bai Y R, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007;85:327–335.
   PubMed Web of Science ®Google Scholar
• Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, Funk GF, Graham SM, Menda Y, Buatti JM. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004;60:1410–1418.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56–68.
   PubMed Web of Science ®Google Scholar
• Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, Chetty IJ, Normolle D, Eisbruch A, Lawrence TS. A pilot study off [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007;25: 3116–3123.
   PubMed Web of Science ®Google Scholar
• Brun E, Ohlsson T, Erlandsson K, Kjellén E, Sandell A, Tennvall J, Wennerberg J, Strand SE. Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. Acta Oncol 1997;36:741–747.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–150S.
   PubMed Web of Science ®Google Scholar
• Scarfone C, Lavely WC, Cmelak AJ, Delbeke D, Martin WH, Billheimer D, Hallahan DE. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45: 543–552.
   PubMed Web of Science ®Google Scholar
• Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993;71:2689–2697.
   PubMed Web of Science ®Google Scholar
• Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, Perfekt R, Wennerberg J, Strand SE. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127–135.
   PubMed Web of Science ®Google Scholar
• Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, Park SH, Kim SY, Lee BJ, Kim JH. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211–216.
   PubMed Web of Science ®Google Scholar
• Cheng SH, Yen KL, Jian JJ, Tsai SY, Chu NM, Leu SY, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiat Oncol Biol Phys 2001;50: 717–726.
   PubMed Web of Science ®Google Scholar
• Kong L, Lu JJ, Hu C, Guo X, Wu Y, Zhang Y. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer 2006;107:1287–1293.
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981–991.
   PubMed Web of Science ®Google Scholar
• Tham IW, Lin S, Pan J, Han L, Lu JJ, Wee J. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Am J Clin Oncol 2010;33: 294–299.
   PubMed Web of Science ®Google Scholar
• Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 2009;75:1071–1078.
   PubMed Web of Science ®Google Scholar
• Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 2010;10:39.
   PubMed Web of Science ®Google Scholar
• Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002;86:512–516.
   PubMed Web of Science ®Google Scholar
• Fang FM, Tsai WL, Go SF, Ho MW, Wu JM, Wang CJ, Su CY, Chen WC, Huang EY. Implications of quantitative tumor and nodal regression rates for nasopharyngeal carcinomas after 45 Gy of radiotherapy. Int J Radiat Oncol Biol Phys 2001;50: 961–969.
   PubMed Web of Science ®Google Scholar
• Xie P, Yue J-B, Fu Z, Feng R, Yu J-M. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2010;21: 1078–1082.
   PubMed Web of Science ®Google Scholar
• Yen TC, Lin CY, Wang HM, Huang SF, Liao CT, Kang CJ, Ng SH, Chan SC, Fan KH, Chen IH, Lin WJ, Cheng AJ, Chang JT. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:1307–1314.
   PubMed Web of Science ®Google Scholar
• Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900–908.
   PubMed Web of Science ®Google Scholar
• van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, Ollers M, Houben R, Minken A, Lambin P, De Ruysscher D. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 2007;82:145–152.
   PubMed Web of Science ®Google Scholar
• Geets X, Daisne JF, Tomsej M, Duprez T, Lonneux M, Grégoire V. Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol 2006;78:291–297.
   PubMed Web of Science ®Google Scholar
• Yuan JW, Fen YL, Xian WJ, He XH, Yuan BH, Ye QL. Early monitoring of radiotherapeutic effects of nasopharyngeal carcinoma xenografts in nude mice using 18F-FDG PET-CT imaging. Chin J Cancer 2010;29:374–378.
   PubMedGoogle Scholar